Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5267_Библиотеки_им_академика_М_И_Перельмана
.pdf
239
CTRS
(hyperactivity):
Low dose:
SMD 1.61
(2.69 to 0.53)
Quality: High
K 1, N 58
Medium dose:
SMD 1.35
(2.29 to 0.40)
Quality: High
K 1, N 58
High dose:
SMD 2.37
(3.54 to 1.20)
Quality: High
K 1, N 58
–
–
Various measures:
Low dose: SMD 0.40
(0.95 to 0.15)
Quality: High
K 2, N 78
High dose: SMD 0.84
(1.06 to 0.62)
Quality: High
K 5, N 806
CATQ: Medium dose:
SMD 1.69
(2.24 to 1.14)
Quality: High
K 1, N 136
CPRS:
Low dose: SMD 0.66
(0.06 to 1.37)
CTRS:
SMD 111
(2.07 to 0.15)
Quality: High
K 1, N 20
–
CPRS:
SMD 1.29
(2.27 to 0.3)
Benefits
ADHD core
symptoms (mean
at endpoint)
(teacher-rated)
ADHD core
symptoms
(mean change)
(teacher-rated)
ADHD core
symptoms
(mean at
–
–
–
–
–
–
Continued
240
In pre-school In school-age children In adults
children
Methylphenidate versus placebo Methylphenidate Methylphenidate
versus waitlist versus placebo
Mixed Mixed comorbidity Specific comorbidity Mixed Mixed comorbidity
comorbidity (developmental comorbidity
reading disorder)
Table 25: (Continued)
endpoint)
(parent-rated)
ADHD core
symptoms (mean
change)
(parent-rated)
ADHD core
symptoms (mean
at endpoint)
(investigator-
rated)
–
–
Quality: high
K 1, N 48
High dose: SMD 0.79
(1.14 to 0.45)
Quality: High
K 4, N 747
Various measures:
Medium dose:
SMD 1.34
(3.26 to 0.58)
Quality: High
K 2, N 186
–
–
–
Quality:
Moderate
K 1, N 20
–
–
–
AISRS:
High dose: SMD 1.40
(1.80 to 1.01)
Quality: Moderate
K 1, N 146
241
–
–
–
–
–
Various measures:
Low dose: SMD 0.43
(1.13 to 0.27)
Quality: Moderate
K 1, N 48
High dose: SMD 0.58
(0.84 to 0.31)
Quality: High
K 4, N 485
IOWA (oppositional/defiant):
Medium dose:
SMD 1.21
(1.72 to 0.71)
Quality: High
K 1, N 136
Various measures:
High dose: SMD 0.73
(1.06 to 0.41)
Quality: High
K 2, N 378
–
–
–
–
ADHD core
symptoms (mean
at endpoint)
(self-report)
Conduct problems
(mean at
endpoint)
(teacher-rated)
Conduct problems
(mean change)
(teacher-rated)
Conduct problems
(mean at
endpoint)
(parent-rated)
–
–
–
–
ADHD-RS (total):
Medium dose:
SMD 0.29
(0.88 to 0.30)
Quality: Moderate
K 1, N 45
–
–
–
Continued
242
In pre-school In school-age children In adults
children
Methylphenidate versus placebo Methylphenidate Methylphenidate
versus waitlist versus placebo
Mixed Mixed comorbidity Specific comorbidity Mixed Mixed comorbidity
comorbidity (developmental comorbidity
reading disorder)
Table 25: (Continued)
Clinical
improvement
(clinician-rated)
Clinical
improvement
(parent and
teacher)
–
SNAP:
RR 1.61
(0.70 to 3.74)
Quality:
Moderate
K 1, N 114
Various measures:
Medium dose: RR 3.08
(1.40 to 6.78)
Quality: High
K 2, N 186
High dose: RR 1.81
(1.46 to 2.24)
Quality: High
K 5, N 823
–
–
–
–
–
AISRS 50% decrease:
High dose: RR 2.16
(1.46 to 3.20)
Quality: High
K 1, N 149
–
243
–
–
–
–
–
–
High dose: NNTH 12
(7 to 33)
Quality: High
K 3, N 318
High dose: NNTH 16
(11 to 50)
Quality: High
K 4, N 634
High dose: NNTH 3
(NNTH 1 to ∞ to NNTB 50)
Quality: Moderate
K 1, N 1
High dose: NNTH 14
(NNTH 4 to ∞ to NNTB 16)
Quality: Moderate
K 2, N 119
High dose: NNTH 16
(NNTH 8 to ∞ to NNTB 100)
Quality: High
K 2, N 141
High dose: NNTH 20
(NNTH 5 to ∞ to NNTB 13)
–
–
–
–
–
–
Harms
Insomnia
Anorexia
Increased crying
Increased
irritability
Moodiness
Thirst
–
–
–
–
–
–
High dose: NNTH 7
(4 to 50)
Quality: High
K 1, K 149
–
–
–
High dose: NNTH 100
(NNTH 20 to ∞ to
NNTB 50)
Quality: Moderate
K 1, N 149
High dose: NNTH 3
(2 to 6)
Continued
244
In pre-school In school-age children In adults
children
Methylphenidate versus placebo Methylphenidate Methylphenidate
versus waitlist versus placebo
Mixed Mixed comorbidity Specific comorbidity Mixed Mixed comorbidity
comorbidity (developmental comorbidity
reading disorder)
Table 25: (Continued)
Itching
Diarrhoea
Palpitations
–
–
–
Quality: Moderate
K 1, N 41
High dose: NNTH 10
(NNTH 4 to ∞ to NNTB 20)
Quality: Moderate
K 1, N 41
High dose: NNTH 50
(NNTH 20 to ∞ to NNTB 100)
Quality: High
K 3, N 318
High dose: NNTH 20
(NNTH 5 to ∞ to NNTB 13)
Quality: Moderate
K 1, N 41
–
–
–
–
–
–
Quality: High
K 1, N 149
–
–
–
–
–
–
–
–
–
High dose: NNTH 20
(NNTH 5 to ∞ to NNTB 13)
Quality: Moderate
K 1, N 41
High dose: NNTH 20
(NNTH 5 to ∞ to NNTB 13)
Quality: Moderate
K 1, N 41
High dose: NNTH 20
(NNTH 5 to ∞ to NNTB 13)
Quality: Moderate
K 1, N 41
High dose: NNTH 20
(NNTH 5 to ∞ to NNTB 13)
Quality: Moderate
K 1, N 41
High dose: NNTH 9
(5 to 50)
Quality: Moderate
K 1, N 100
High dose: NNTH 9
(5 to 50)
Quality: Moderate
K 1, N 59
–
–
–
–
–
–
Stuttering
Negativism
Reddened eyes
Incoherent speech
7% decrease in
bodyweight
Decreased
appetite
–
–
–
–
–
–
–
–
–
–
High dose: NNTH 3
(2 to 5)
Quality: High
K 1, N 149
Continued
245
246
In pre-school In school-age children In adults
children
Methylphenidate versus placebo Methylphenidate Methylphenidate
versus waitlist versus placebo
Mixed Mixed comorbidity Specific comorbidity Mixed Mixed comorbidity
comorbidity (developmental comorbidity
reading disorder)
Table 25: (Continued)
Gastrointestinal
problems
Tension
Cardiovascular
complaints
Depression
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
High dose: NNTH 6
(2 to 6)
Quality: High
K 1, N 149
High dose: NNTH 5
(3 to 11)
Quality: High
K 1, N 149
High dose: NNTH 12
(6 to ∞)
Quality: Moderate
K 1, N 149
High dose: NNTH 14
(7 to 100)
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
Dizziness
Anxiety
Autonomic
symptoms
Increased energy
Tics
–
–
–
–
–
Quality: Moderate
K 1, N 149
High dose: NNTH 14
(7 to 100)
Quality: Moderate
K 1, N 149
High dose: NNTH 16
(8 to ∞)
Quality: Moderate
K 1, N 149
High dose: NNTH 33
(NNTH 11 to ∞ to
NNTB 50)
Quality: Moderate
K 1, N 149
High dose: NNTH 33
(NNTH 11 to ∞ to
NNTB 50)
Quality: Moderate
K 1, N 149
High dose: NNTH 33
(NNTH 12 to ∞ to
NNTB 50)
Quality: Moderate
K 1, N 149
Continued
247
248
In pre-school In school-age children In adults
children
Methylphenidate versus placebo Methylphenidate Methylphenidate
versus waitlist versus placebo
Mixed Mixed comorbidity Specific comorbidity Mixed Mixed comorbidity
comorbidity (developmental comorbidity
reading disorder)
Table 25: (Continued)
Skin problems
Easy bruising
Sexual problems
–
–
–
–
–
–
–
–
–
–
–
–
High dose: NNTH 100
(NNTH 20 to ∞ to
NNTB 50)
Quality: Moderate
K 1, N 149
High dose: NNTH 100
(NNTH 20 to ∞ to
NNTB 50)
Quality: Moderate
K 1, N 149
High dose: NNTH 100
(NNTH 20 to ∞ to
NNTB 50)
Соседние файлы в папке Библиотека им академика М.И. Перельмана